01
Cash & equivalents decreased 71.7%
Cash & equivalents changed -71.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$44.1M→$12.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTPMV Pharmaceuticals, Inc.'s latest supported as-filed period reports net income of -$18.1M, 14.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -71.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed +14.7% from the comparable as-filed period.
Operating income changed +17.5% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
PMVP · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-350448SEC ↗8-KAug 14, 2026Period Aug 14, 20260001193125-26-350445SEC ↗4Jun 5, 2026Period Jun 4, 20260001644348-26-000003SEC ↗4Jun 5, 2026Period Jun 4, 20260001124164-26-000002SEC ↗4Jun 5, 2026Period Jun 4, 20260001329959-26-000002SEC ↗4Jun 5, 2026Period Jun 4, 20260001797209-26-000002SEC ↗4Jun 5, 2026Period Jun 4, 20260001579824-26-000003SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 4, 2026Filed Jun 5, 2026 | Stelzer LaurieDirector | Grant Or AwardDirect | 42,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -20.2% from the comparable as-filed period.
Stock-based compensation changed -7.5% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-258466